• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西卫生监管体系在国家患者安全演变中的主导作用:历史、困境和当前挑战。

The Protagonism of the Brazilian Health Regulatory System in the Evolution of Patient Safety in the Country: History, Dilemmas, and Current Challenges.

机构信息

From the General Management of Technology in Health Services - GGTES/Brazilian Health Regulatory Agency (ANVISA), Brasilia, Brazil.

出版信息

J Patient Saf. 2020 Dec;16(4):e260-e266. doi: 10.1097/PTS.0000000000000671.

DOI:10.1097/PTS.0000000000000671
PMID:32084092
Abstract

OBJECTIVE

This article aims to identify and analyze the legal and regulatory frameworks with an interface with patient safety, considering the historical path of the patient safety policy in Brazil.

METHODS

This is a historical review based on the relevant literature to the topic such as papers, legislation, and official documents with an interface with public health policies from 1988 to 2019. We also performed a documentary search to include data from the Brazilian Health Regulatory Agency (ANVISA) such as normative and nonnormative regulatory instruments. After organizing the data, the process of content analysis was performed.

RESULTS

We debated initially the historical aspects of sanitary surveillance of health services in addition to main actions taken by the Brazilian Health Regulatory System, which includes sanitary regulation and patient safety challenges. We identified a diversity of regulations published by ANVISA in the past decade related to patient safety, in addiction to sanitary actions. These initiatives culminated in the establishment of the National Patient Safety Program in 2013, followed by other health improvements, such as surveillance, incidents monitoring, and safe practices self-assessment.

CONCLUSIONS

The regulation and sanitary actions directed to patient safety in Brazil have increased after the creation of ANVISA. In the face of this activities, the social role played by the Brazilian Health Regulatory System toward the advancement in the field of risk minimization in health services can be highlighted as a protagonist in the process of promoting patient safety.

摘要

目的

本文旨在识别和分析与患者安全相关的法律和监管框架,考虑到巴西患者安全政策的历史发展路径。

方法

这是一项基于相关文献的历史回顾,包括与 1988 年至 2019 年期间公共卫生政策相关的论文、立法和官方文件等主题的文献。我们还进行了文献检索,以纳入巴西卫生监管机构(ANVISA)的数据,如规范和非规范监管文书。在整理数据后,我们进行了内容分析。

结果

我们首先讨论了卫生服务卫生监督的历史方面,以及巴西卫生监管系统采取的主要行动,其中包括卫生监管和患者安全挑战。我们发现,ANVISA 在过去十年中发布了许多与患者安全相关的法规,除此之外还有卫生行动。这些举措最终促成了 2013 年国家患者安全计划的建立,随后还采取了其他改善措施,如监督、事件监测和安全实践自我评估。

结论

在 ANVISA 成立后,巴西针对患者安全的监管和卫生行动有所增加。面对这些活动,巴西卫生监管系统在减少卫生服务风险领域的发展中所扮演的社会角色,可以被视为促进患者安全的主角。

相似文献

1
The Protagonism of the Brazilian Health Regulatory System in the Evolution of Patient Safety in the Country: History, Dilemmas, and Current Challenges.巴西卫生监管体系在国家患者安全演变中的主导作用:历史、困境和当前挑战。
J Patient Saf. 2020 Dec;16(4):e260-e266. doi: 10.1097/PTS.0000000000000671.
2
[Sanitary regulation as part of health policy in Brazil: gaps and challenges].[巴西卫生政策中的卫生法规:差距与挑战]
Rev Panam Salud Publica. 2016 May;39(5):226-231.
3
Vaccines in Brazil: historical analysis of the Sanitary registration and vaccine availability in the Brazilian Unified Health System.巴西的疫苗接种:巴西统一卫生系统中卫生登记和疫苗供应的历史分析。
Cien Saude Colet. 2021 Nov;26(11):5509-5522. doi: 10.1590/1413-812320212611.13932021. Epub 2021 Jul 9.
4
Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency.巴西药物警戒系统的演变与关键要素:一项从巴西卫生监管机构创建开始的范围综述
Cad Saude Publica. 2018 Oct 11;34(10):e00000218. doi: 10.1590/0102-311X00000218.
5
Patient safety incidents and adverse events reported by Brazilian citizens: a descriptive study, 2014-2018.2014-2018 年巴西公民报告的患者安全事件和不良事件:描述性研究。
Epidemiol Serv Saude. 2021 Nov 26;30(4):e2021005. doi: 10.1590/S1679-49742021000400007. eCollection 2021.
6
Health protection in Brazil: the National Sanitary Surveillance System.巴西的卫生防护:国家卫生监督系统。
Cien Saude Colet. 2017 Oct;22(10):3225-3234. doi: 10.1590/1413-812320172210.16672017.
7
Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?巴西卫生监管局发布的十三年药物警戒信息:情况如何?
J Eval Clin Pract. 2020 Jun;26(3):957-961. doi: 10.1111/jep.13233. Epub 2019 Jul 10.
8
Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.巴西药物警戒法规的协调统一:改善风险沟通的机会。
Clin Ther. 2019 Mar;41(3):598-603. doi: 10.1016/j.clinthera.2019.01.013. Epub 2019 Feb 18.
9
Three decades of telemedicine in Brazil: Mapping the regulatory framework from 1990 to 2018.巴西三十年的远程医疗:1990 年至 2018 年的监管框架绘制。
PLoS One. 2020 Nov 25;15(11):e0242869. doi: 10.1371/journal.pone.0242869. eCollection 2020.
10
Pharmacovigilance risk mitigation plans: action in public health to promote the safe use of medication.药物警戒风险缓解计划:公共卫生领域为促进药物安全使用而采取的行动。
Cien Saude Colet. 2015 Dec;20(12):3897-905. doi: 10.1590/1413-812320152012.16442014.